亞太地區的體外診斷市場預測:臨床化學檢驗·遺傳基因檢驗·血液檢驗·組織/細胞檢驗，免疫化學檢查·感染/免疫疾病檢驗·微生物學培養檢驗

亞太地區的體外診斷市場預測:臨床化學檢驗·遺傳基因檢驗·血液檢驗·組織/細胞檢驗，免疫化學檢查·感染/免疫疾病檢驗·微生物學培養檢驗 是由出版商GlobalData在2011年12月所出版的。 這份英文市場調查報告書包含Pages: 252 價格從美金3500起跳。

簡介

本報告提供亞太地區的體外診斷市場相關資料，市場整體及各國分析、各國總收益實績及預測資料、加上企業及流通管道佔有率資料、各開發平台產品分析、體外診斷市場相關法規、財務交易狀況、主要企業的簡介等資料彙整，為您概述為以下內容。

1 目錄

1 目錄

• 1.1 表格一覽
• 1.2 圖表一覽

2 簡介

• 2.1 關於本報告

3 體外診斷 - 亞太地區

• 3.1 體外診斷 多國間比較, USD 以實額為基礎, 實際成果及預測
• 3.2 體外診斷, 亞太地區, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
• 3.3 體外診斷, 亞太地區, 企業佔有率

4 體外診斷 - 澳洲

• 4.1 體外診斷, 澳洲, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
• 4.2 體外診斷, 澳洲, 流通佔有率
• 4.3 體外診斷, 澳洲, 企業佔有率

5 體外診斷 - 日本

• 5.1 體外診斷, 日本, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
• 5.2 體外診斷, 日本, 流通佔有率
• 5.3 體外診斷, 日本, 企業佔有率 (

6 體外診斷 - 印度

• 6.1 體外診斷, 印度, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
• 6.2 體外診斷, 印度, 流通佔有率
• 6.3 體外診斷, 印度, 企業佔有率

7 體外診斷 - 中國

• 7.1 體外診斷, 中國, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
• 7.2 體外診斷, 中國, 流通佔有率
• 7.3 體外診斷, 中國, 企業佔有率

8 主要企業概要 - 亞太地區 體外診斷 市場

• 8.1 F. Hoffmann-La Roche Ltd.
• 8.2 Siemens Healthcare
• 8.3 Abbott Laboratories
• 8.4 Sysmex Corporation
• 8.5 Beckman Coulter, Inc.
• 8.6 Ortho-Clinical Diagnostics Inc.
• 8.7 Becton, Dickinson and Company
• 8.8 bioMerieux S.A.
• 8.9 Bio-Rad Laboratories, Inc.
• 8.10 Eiken Chemical Co.,Ltd.
• 8.11 Qiagen N.V.
• 8.12 Phadia AB
• 8.13 Alere Inc.
• 8.14 Mindray Medical International Limited
• 8.15 Transasia Bio-Medicals Ltd.
• 8.16 DiaSorin S.p.A
• 8.17 Shanghai Kehua Bio-engineering Co., Ltd.
• 8.18 Gen-Probe Incorporated
• 8.19 日本光電
• 8.20 堀場製作所
• 8.21 Tosoh
• 8.22 Danaher Corporation
• 8.23 PerkinElmer, Inc.
• 8.24 Span Diagnostics Ltd.
• 8.25 Grifols, S.A.
• 8.26 Trivitron Healthcare Pvt Ltd.
• 8.27 Life Technologies Corporation
• 8.28 J.Mitra & Co. Pvt Ltd
• 8.29 Thermo Fisher Scientific Inc.
• 8.30 DIAGNOSTICA STAGO, Inc.
• 8.31 Olympus Corporation
• 8.32 Tulip Group
• 8.33 Immucor, Inc.

9 體外診斷 市場 開發中產品

• 9.1 臨床化學檢驗 市場 開發中產品
• 9.2 免疫化學檢查 市場 開發中產品
• 9.3 血液檢驗 市場 開發中產品
• 9.4 感染/免疫疾病檢驗 市場 開發中產品
• 9.5 微生物學培養檢驗 市場 開發中產品
• 9.6 組織/細胞檢驗 市場 開發中產品
• 9.7 遺傳基因檢驗 市場 開發中產品

10 財務交易展望

• 10.1 收購
• 10.2 合作

11 最新趨勢

• 11.1 策略及產業計畫
• 11.2 法律行為及法規
• 11.3 政府及公益相關
• 11.4 產品資訊

12 附錄

• 12.1 調查對象的市場定義
• 12.2 調查方法
• 12.3 二級研究
• 12.4 主要研究
• 12.5 資料的模式化
• 12.6 預測
• 12.7 專門委員會
• 12.8 GlobalData 諮詢服務
• 12.9 貨幣換算
• 12.10 諮詢方式
• 12.11 免責聲明

表格一覽

1.1 表格一覽

• 表格 1: 體外診斷, 多國間比較, USD 以實額為基礎, 實際成果及預測
• 表格 2: 體外診斷, 亞太地區, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
• 表格 3: 體外診斷, 亞太地區, 分類間分析, 實際成果及預測
• 表格 4: 體外診斷, 亞太地區, 整體收益 ($m), USD 以實額為基礎, 實際成果
• 表格 5: 體外診斷, 亞太地區, 整體收益 ($m), USD 以實額為基礎，預測
• 表格 6: 體外診斷, 亞太地區, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 7: 體外診斷, 澳洲, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
• 表格 8: 體外診斷, 澳洲, 整體收益 ($m), USD 以實額為基礎, 實際成果
• 表格 9: 體外診斷, 澳洲, 整體收益 ($m), USD 以實額為基礎，預測
• 表格 10: 臨床化學檢驗, 澳洲, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 11: 免疫化學檢查, 澳洲, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 12: 遺傳基因檢驗, 澳洲, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 13: 血液檢驗, 澳洲, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 14: 組織/細胞檢驗, 澳洲, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 15: 感染/免疫疾病檢驗, 澳洲, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 16: 微生物學培養檢驗, 澳洲, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 17: 體外診斷, 澳洲, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 18: 臨床化學檢驗, 澳洲, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 19: 遺傳基因檢驗, 澳洲, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 20: 血液檢驗, 澳洲, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 21: 組織/細胞檢驗, 澳洲, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 22: 免疫化學檢查, 澳洲, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 23: 感染/免疫疾病檢驗, 澳洲, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 24: 微生物學培養檢驗, 澳洲, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 25: 體外診斷, 日本, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
• 表格 26: 體外診斷, 日本, 整體收益 ($m), USD 以實額為基礎, 實際成果
• 表格 27: 體外診斷, 日本, 整體收益 ($m), USD 以實額為基礎，預測
• 表格 28: 臨床化學檢驗, 日本, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 29: 遺傳基因檢驗, 日本, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 30: 血液檢驗, 日本, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 31: 組織/細胞檢驗, 日本, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 32: 免疫化學檢查, 日本, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 33: 感染/免疫疾病檢驗, 日本, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 34: 微生物學培養檢驗, 日本, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 35: 體外診斷, 日本, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 36: 臨床化學檢驗, 日本, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 37: 遺傳基因檢驗, 日本, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 38: 血液檢驗, 日本, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 39: 組織/細胞檢驗, 日本, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 40: 免疫化學檢查, 日本, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 41: 感染/免疫疾病檢驗, 日本, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 42: 微生物學培養檢驗, 日本, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 43: 體外診斷, 印度, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
• 表格 44: 體外診斷, 印度, 整體收益 ($m), USD 以實額為基礎, 實際成果
• 表格 45: 體外診斷, 印度, 整體收益 ($m), USD 以實額為基礎，預測
• 表格 46: 臨床化學檢驗, 印度, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 47: 遺傳基因檢驗, 印度, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 48: 血液檢驗, 印度, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 49: 組織/細胞檢驗, 印度, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 50: 免疫化學檢查, 印度, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 51: 感染/免疫疾病檢驗, 印度, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 52: 微生物學培養檢驗, 印度, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 53: 體外診斷, 印度, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 54: 臨床化學檢驗, 印度, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 55: 遺傳基因檢驗, 印度, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 56: 血液檢驗, 印度, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 57: 組織/細胞檢驗, 印度, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 58: 免疫化學檢查, 印度, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 59: 感染/免疫疾病檢驗, 印度, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 60: 微生物學培養檢驗, 印度, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 61: 體外診斷, 中國, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
• 表格 62: 體外診斷, 中國, 整體收益 ($m), USD 以實額為基礎, 實際成果
• 表格 63: 體外診斷, 中國, 整體收益 ($m), USD 以實額為基礎，預測
• 表格 64: 臨床化學檢驗, 中國, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 65: 遺傳基因檢驗, 中國, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 66: 血液檢驗, 中國, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 67: 組織/細胞檢驗, 中國, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 68: 免疫化學檢查, 中國, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 69: 感染/免疫疾病檢驗, 中國, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 70: 微生物學培養檢驗, 中國, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 71: 體外診斷, 中國, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 72: 臨床化學檢驗, 中國, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 73: 遺傳基因檢驗, 中國, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 74: 血液檢驗, 中國, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 75: 組織/細胞檢驗, 中國, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 76: 免疫化學檢查, 中國, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 77: 感染/免疫疾病檢驗, 中國, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 78: 微生物學培養檢驗, 中國, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 79: 臨床化學檢驗 市場 開發中產品
• 表格 80: 免疫化學檢查 市場 開發中產品
• 表格 81: 血液檢驗 市場 開發中產品
• 表格 82: 感染/免疫疾病檢驗 市場 開發中產品
• 表格 83: 微生物學培養檢驗 市場 開發中產品
• 表格 84: 組織/細胞檢驗 市場 開發中產品
• 表格 85: 遺傳基因檢驗 市場 開發中產品
• 表格 86∼129: 體外診斷市場, 亞太地區, 交易內容詳細內容
• 表格 130: 美金V.S.該地貨幣, 亞太地區, 平均匯率

圖表一覽

1.2 圖表一覽

• 圖 1: 體外診斷, 多國間比較, USD 以實額為基礎, 實際成果及預測
• 圖 2: 體外診斷, 亞太地區, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
• 圖 3: 體外診斷, 亞太地區, 分類間分析, 實際成果及預測
• 圖 4: 體外診斷, 亞太地區, 整體收益 ($m), USD 以實額為基礎, 實際成果
• 圖 5: 體外診斷, 亞太地區, 整體收益 ($m), USD 以實額為基礎，預測
• 圖 6: 體外診斷, 亞太地區, 企業佔有率 (%)
• 圖 7: 體外診斷, 澳洲, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
• 圖 8: 體外診斷, 澳洲, 整體收益 ($m), USD 以實額為基礎, 實際成果
• 圖 9: 體外診斷, 澳洲, 整體收益 ($m), USD 以實額為基礎，預測
• 圖 10: 體外診斷, 澳洲, 企業佔有率 (%)
• 圖 11: 臨床化學檢驗, 澳洲, 企業佔有率 (%)
• 圖 12: 遺傳基因檢驗, 澳洲, 企業佔有率 (%)
• 圖 13: 血液檢驗, 澳洲, 企業佔有率 (%)
• 圖 14: 組織/細胞檢驗, 澳洲, 企業佔有率 (%)
• 圖 15: 免疫化學檢查, 澳洲, 企業佔有率 (%)
• 圖 16: 感染/免疫疾病檢驗, 澳洲, 企業佔有率 (%)
• 圖 17: 微生物學培養檢驗, 澳洲, 企業佔有率 (%)
• 圖 18: 體外診斷, 日本, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
• 圖 19: 體外診斷, 日本, 整體收益 ($m), USD 以實額為基礎, 實際成果
• 圖 20: 體外診斷, 日本, 整體收益 ($m), USD 以實額為基礎，預測
• 圖 21: 體外診斷, 日本, 企業佔有率 (%)
• 圖 22: 臨床化學檢驗, 日本, 企業佔有率 (%)
• 圖 23: 遺傳基因檢驗, 日本, 企業佔有率 (%)
• 圖 24: 血液檢驗, 日本, 企業佔有率 (%)
• 圖 25: 組織/細胞檢驗, 日本, 企業佔有率 (%)
• 圖 26: 免疫化學檢查, 日本, 企業佔有率 (%)
• 圖 27: 感染/免疫疾病檢驗, 日本, 企業佔有率 (%)
• 圖 28: 微生物學培養檢驗, 日本, 企業佔有率 (%)
• 圖 29: 體外診斷, 印度, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
• 圖 30: 體外診斷, 印度, 整體收益 ($m), USD 以實額為基礎, 實際成果
• 圖 31: 體外診斷, 印度, 整體收益 ($m), USD 以實額為基礎，預測
• 圖 32: 體外診斷, 印度, 企業佔有率 (%)
• 圖 33: 臨床化學檢驗, 印度, 企業佔有率 (%)
• 圖 34: 遺傳基因檢驗, 印度, 企業佔有率 (%)
• 圖 35: 血液檢驗, 印度, 企業佔有率 (%)
• 圖 36: 組織/細胞檢驗, 印度, 企業佔有率 (%)
• 圖 37: 免疫化學檢查, 印度, 企業佔有率 (%)
• 圖 38: 感染/免疫疾病檢驗, 印度, 企業佔有率 (%)
• 圖 39: 微生物學培養檢驗, 印度, 企業佔有率 (%)
• 圖 40: 體外診斷, 中國, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
• 圖 41: 體外診斷, 中國, 整體收益 ($m), USD 以實額為基礎, 實際成果
• 圖 42: 體外診斷, 中國, 整體收益 ($m), USD 以實額為基礎，預測
• 圖 43: 體外診斷, 中國, 企業佔有率 (%)
• 圖 44: 臨床化學檢驗, 中國, 企業佔有率 (%)
• 圖 45: 遺傳基因檢驗, 中國, 企業佔有率 (%)
• 圖 46: 血液檢驗, 中國, 企業佔有率 (%)
• 圖 47: 組織/細胞檢驗, 中國, 企業佔有率 (%)
• 圖 48: 免疫化學檢查, 中國, 企業佔有率 (%)
• 圖 49: 感染/免疫疾病檢驗, 中國, 企業佔有率 (%)
• 圖 50: 微生物學培養檢驗, 中國, 企業佔有率 (%)
• 圖 51: F. Hoffmann-La Roche Ltd., 企業佔有率 (%), 亞太地區 體外診斷 市場
• 圖 52: Siemens Healthcare, 企業佔有率 (%), 亞太地區 體外診斷 市場
• 圖 53: Abbott Laboratories, 企業佔有率 (%), 亞太地區 體外診斷 市場
• 圖 54: Sysmex Corporation, 企業佔有率 (%), 亞太地區 體外診斷 市場
• 圖 55: Beckman Coulter, Inc., Company Shar (%), 亞太地區 體外診斷 市場
• 圖 56: Ortho-Clinical Diagnostics Inc., 企業佔有率 (%), 亞太地區 體外診斷 市場

目錄

Abstract

Asia-Pacific In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

Summary

GlobalData's new report, "Asia-Pacific In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture" provides key market data on the Asia-Pacific In Vitro Diagnostics market - Australia, China, India and Japan. The report provides value (USD million) data for all the market categories - Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

• Countries covered include Australia, China, India and Japan.
• Market size and company share data for In Vitro Diagnostics market categories - Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.
• Annualized market revenues (USD million) data for each of the market categories in each of the country. Data from 2003 to 2010, forecast forward for 7 years to 2017.
• 2010 company shares and distribution shares data for each of the market categories and countries.
• Global corporate-level profiles of key companies operating within the Asia-Pacific In Vitro Diagnostics market..
• Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, Sysmex Corporation, Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc. and others.

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the Asia-Pacific In Vitro Diagnostics competitive landscape.
• Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
• What are the key distribution channels and what's the most preferred mode of product distribution - Identify, understand and capitalize.

TOC

1 Table of Contents

1 Table of Contents 2

• 1.1 List of Tables 6
• 1.2 List of Figures 10

2 Introduction 12

• 2.1 What is This Report About? 12

3 In Vitro Diagnostics in Asia-Pacific 13

• 3.1 In Vitro Diagnostics Cross Country Comparison, USD Actual, 2003-2017 13
• 3.2 In Vitro Diagnostics, Asia-Pacific, Overall Revenue ($m), USD Actual, 2003-2017 14
• 3.3 In Vitro Diagnostics, Asia-Pacific, Company share (2009-2010) 22

4 In Vitro Diagnostics in Australia 24

• 4.1 In Vitro Diagnostics, Australia, Overall Revenue ($m), USD Actual, 2003-2017 24
• 4.2 In Vitro Diagnostics, Australia, Distribution Share (2009-2010) 30
• 4.3 In Vitro Diagnostics, Australia, Company share (2009-2010) 34

5 In Vitro Diagnostics In Japan 50

• 5.1 In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Actual, 2003-2017 50
• 5.2 In Vitro Diagnostics, Japan, Distribution Share (2009-2010) 56
• 5.3 In Vitro Diagnostics, Japan, Company Share (2009-2010 60

6 In Vitro Diagnostics In India 76

• 6.1 In Vitro Diagnostics, India, Overall Revenue ($m), USD Actual, 2003-2017 76
• 6.2 In Vitro Diagnostics, India, Distribution Share (2009-2010) 82
• 6.3 In Vitro Diagnostics, India, Company Share (2009-2010) 86

7 In Vitro Diagnostics In China 102

• 7.1 In Vitro Diagnostics, China, Overall Revenue ($m), USD Actual, 2003-2017 102
• 7.2 In Vitro Diagnostics, China, Distribution Share (2009-2010) 108
• 7.3 In Vitro Diagnostics, China, Company share (2009-2010) 112

8 Overview of Key Companies in Asia-Pacific In Vitro Diagnostics Market 128

• 8.1 F. Hoffmann-La Roche Ltd. 128
• 8.2 Siemens Healthcare 129
• 8.3 Abbott Laboratories 130
• 8.4 Sysmex Corporation 131
• 8.5 Beckman Coulter, Inc. 132
• 8.6 Ortho-Clinical Diagnostics Inc. 133
• 8.7 Becton, Dickinson and Company 134
• 8.8 bioMerieux S.A. 134
• 8.9 Bio-Rad Laboratories, Inc. 134
• 8.10 Eiken Chemical Co.,Ltd. 135
• 8.11 Qiagen N.V. 135
• 8.12 Phadia AB 135
• 8.13 Alere Inc. 136
• 8.14 Mindray Medical International Limited 136
• 8.15 Transasia Bio-Medicals Ltd. 136
• 8.16 DiaSorin S.p.A 137
• 8.17 Shanghai Kehua Bio-engineering Co., Ltd. 137
• 8.18 Gen-Probe Incorporated 137
• 8.19 Nihon Kohden Corporation 138
• 8.20 HORIBA, Ltd. 138
• 8.21 Tosoh Corporation 139
• 8.22 Danaher Corporation 139
• 8.23 PerkinElmer, Inc. 139
• 8.24 Span Diagnostics Ltd. 140
• 8.25 Grifols, S.A. 140
• 8.26 Trivitron Healthcare Pvt Ltd. 141
• 8.27 Life Technologies Corporation 141
• 8.28 J.Mitra & Co. Pvt Ltd 141
• 8.29 Thermo Fisher Scientific Inc. 142
• 8.30 DIAGNOSTICA STAGO, Inc. 142
• 8.31 OLYMPUS CORPORATION 143
• 8.32 Tulip Group 143
• 8.33 Immucor, Inc. 143

9 In Vitro Diagnostics Market Pipeline Products 144

• 9.1 Clinical Chemisty Market Pipeline Products 144
• 9.2 Immuno Chemistry Market Pipeline Products 146
• 9.3 Haematology Market Pipeline Products 149
• 9.4 Infectious Immunology Market Pipeline Products 151
• 9.5 Microbiology Culture Market Pipeline Products 155
• 9.6 Histology and Cytology Market Pipeline Products 156
• 9.7 Genetic Testing Market Pipeline Products 157

10 Financial Deals Landscape 161

• 10.1 Acquisition 161
• 10.2 Partnerships 164

11 Recent Developments 205

• 11.1 Strategy And Business Planning 205
• 11.2 Legal and Regulatory 213
• 11.3 Government and Public Interest 216
• 11.4 Product News 222

12 Appendix 240

• 12.1 Definitions of Markets Covered in the Report 241
• 12.2 Research Methodology 243
• 12.3 Secondary Research 243
• 12.4 Primary Research 244
• 12.5 Models 244
• 12.6 Forecasts 245
• 12.7 Expert Panels 245
• 12.8 GlobalData Consulting 245
• 12.9 Currency Conversion 246
• 12.10 Contact Us 246
• 12.11 Disclaimer 246

List of Tables

1.1 List of Tables

• Table 1: In Vitro Diagnostics, Cross Country Comparison, USD Actual, 2003-2017 19
• Table 2: In Vitro Diagnostics, Asia-Pacific, Overall Revenue ($m), USD Actual, 2003-2017 21
• Table 3: In Vitro Diagnostics, Asia-Pacific, Cross-Category Analysis, 2003-2017 23
• Table 4: In Vitro Diagnostics, Asia-Pacific, Overall Revenue ($m), USD Actual, Historic, 2003-2010 25
• Table 5: In Vitro Diagnostics, Asia-Pacific, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 27
• Table 6: In Vitro Diagnostics, Asia-Pacific, Company Share by Revenue ($m), USD Actual, 2009-2010 29
• Table 7: In Vitro Diagnostics, Australia, Overall Revenue ($m), USD Actual, 2003-2017 31
• Table 8: In Vitro Diagnostics, Australia, Overall Revenue ($m), USD Actual, Historic, 2003-2010 33
• Table 9: In Vitro Diagnostics, Australia, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 35
• Table 10: Clinical Chemistry, Australia, Distribution Share by Revenue ($m), USD Actual, 2009-2010 36
• Table 11: Immuno Chemistry, Australia, Distribution Share by Revenue ($m), USD Actual, 2009-2010 36
• Table 12: Genetic Testing, Australia, Distribution Share by Revenue ($m), USD Actual, 2009-2010 37
• Table 13: Haematology, Australia, Distribution Share by Revenue ($m), USD Actual, 2009-2010 37
• Table 14: Histology and Cytology, Australia, Distribution Share by Revenue ($m), USD Actual, 2009-2010 38
• Table 15: Infectious Immunology, Australia, Distribution Share by Revenue ($m), USD Actual, 2009-2010 38
• Table 16: Microbiology Culture, Australia, Distribution Share by Revenue ($m), USD Actual, 2009-2010 39
• Table 17: In Vitro Diagnostics, Australia, Company share by Revenue ($m), USD Actual, 2009-2010 41
• Table 18: Clinical Chemistry, Australia, Company share by Revenue ($m), USD Actual 2009-2010 43
• Table 19: Genetic Testing, Australia, Company share by Revenue ($m), USD Actual 2009-2010 45
• Table 20: Haematology, Australia, Company share by Revenue ($m), USD Actual 2009-2010 47
• Table 21: Histology and Cytology, Australia, Company share by Revenue ($m), USD Actual 2009-2010 49
• Table 22: Immuno Chemistry, Australia, Company share by Revenue ($m), USD Actual 2009-2010 51
• Table 23: Infectious Immunology, Australia, Company share by Revenue ($m), USD Actual 2009-2010 53
• Table 24: Microbiology Culture, Australia, Company share by Revenue ($m), USD Actual 2009-2010 55
• Table 25: In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Actual, 2003-2017 57
• Table 26: In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Actual, Historic, 2003-2010 59
• Table 27: In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 61
• Table 28: Clinical Chemistry, Japan, Distribution Share by Revenue ($m), USD Actual, 2009-2010 62
• Table 29: Genetic Testing, Japan, Distribution Share by Revenue ($m), USD Actual, 2009-2010 62
• Table 30: Haematology, Japan, Distribution Share by Revenue ($m), USD Actual, 2009-2010 63
• Table 31: Histology and Cytology, Japan, Distribution Share by Revenue ($m), USD Actual, 2009-2010 63
• Table 32: Immuno Chemistry, Japan, Distribution Share by Revenue ($m), USD Actual, 2009-2010 64
• Table 33: Infectious Immunology, Japan, Distribution Share by Revenue ($m), USD Actual, 2009-2010 64
• Table 34: Microbiology Culture, Japan, Distribution Share by Revenue ($m), USD Actual, 2009-2010 65
• Table 35: In Vitro Diagnostics, Japan, Company Share by Revenue ($m), USD Actual, 2009-2010 67
• Table 36: Clinical Chemistry, Japan, Company Share by Revenue ($m), USD Actual 2009-2010 69
• Table 37: Genetic Testing, Japan, Company Share by Revenue ($m), USD Actual 2009-2010 71
• Table 38: Haematology, Japan, Company Share by Revenue ($m), USD Actual 2009-2010 73
• Table 39: Histology and Cytology, Japan, Company Share by Revenue ($m), USD Actual 2009-2010 75
• Table 40: Immuno Chemistry, Japan, Company Share by Revenue ($m), USD Actual 2009-2010 77
• Table 41: Infectious Immunology, Japan, Company Share by Revenue ($m), USD Actual 2009-2010 79
• Table 42: Microbiology Culture, Japan, Company Share by Revenue ($m), USD Actual 2009-2010 81
• Table 43: In Vitro Diagnostics, India, Overall Revenue ($m), USD Actual, 2003-2017 83
• Table 44: In Vitro Diagnostics, India, Overall Revenue ($m), USD Actual, Historic, 2003-2010 85
• Table 45: In Vitro Diagnostics, India, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 87
• Table 46: Clinical Chemistry, India, Distribution Share by Revenue ($m), USD Actual, 2009-2010 88
• Table 47: Genetic Testing, India, Distribution Share by Revenue ($m), USD Actual, 2009-2010 88
• Table 48: Haematology, India, Distribution Share by Revenue ($m), USD Actual, 2009-2010 89
• Table 49: Histology And Cytology, India, Distribution Share by Revenue ($m), USD Actual, 2009-2010 89
• Table 50: Immuno Chemistry, India, Distribution Share by Revenue ($m), USD Actual, 2009-2010 90
• Table 51: Infectious Immunology, India, Distribution Share by Revenue ($m), USD Actual, 2009-2010 90
• Table 52: Microbiology Culture, India, Distribution Share by Revenue ($m), USD Actual, 2009-2010 91
• Table 53: In Vitro Diagnostics, India, Company Share by Revenue ($m), USD Actual, 2009-2010 93
• Table 54: Clinical Chemistry, India, Company Share by Revenue ($m), USD Actual 2009-2010 95
• Table 55: Genetic Testing, India, Company Share by Revenue ($m), USD Actual 2009-2010 97
• Table 56: Haematology, India, Company Share by Revenue ($m), USD Actual 2009-2010 99
• Table 57: Histology And Cytology, India, Company Share by Revenue ($m), USD Actual 2009-2010 101
• Table 58: Immuno Chemistry, India, Company Share by Revenue ($m), USD Actual 2009-2010 103
• Table 59: Infectious Immunology, India, Company Share by Revenue ($m), USD Actual 2009-2010 105
• Table 60: Microbiology Culture, India, Company Share by Revenue ($m), USD Actual 2009-2010 107
• Table 61: In Vitro Diagnostics, China, Overall Revenue ($m), USD Actual, 2003-2017 109
• Table 62: In Vitro Diagnostics, China, Overall Revenue ($m), USD Actual, Historic, 2003-2010 111
• Table 63: In Vitro Diagnostics, China, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 113
• Table 64: Clinical Chemistry, China, Distribution Share by Revenue ($m), USD Actual, 2009-2010 114
• Table 65: Genetic Testing, China, Distribution Share by Revenue ($m), USD Actual, 2009-2010 114
• Table 66: Haematology, China, Distribution Share by Revenue ($m), USD Actual, 2009-2010 115
• Table 67: Histology And Cytology, China, Distribution Share by Revenue ($m), USD Actual, 2009-2010 115
• Table 68: Immuno Chemistry, China, Distribution Share by Revenue ($m), USD Actual, 2009-2010 116
• Table 69: Infectious Immunology, China, Distribution Share by Revenue ($m), USD Actual, 2009-2010 116
• Table 70: Microbiology Culture, China, Distribution Share by Revenue ($m), USD Actual, 2009-2010 117
• Table 71: In Vitro Diagnostics, China, Company share by Revenue ($m), USD Actual, 2009-2010 119
• Table 72: Clinical Chemistry, China, Company share by Revenue ($m), USD Actual 2009-2010 121
• Table 73: Genetic Testing, China, Company share by Revenue ($m), USD Actual 2009-2010 123
• Table 74: Haematology, China, Company share by Revenue ($m), USD Actual 2009-2010 125
• Table 75: Histology And Cytology, China, Company share by Revenue ($m), USD Actual 2009-2010 127
• Table 76: Immuno Chemistry, China, Company share by Revenue ($m), USD Actual 2009-2010 129
• Table 77: Infectious Immunology, China, Company share by Revenue ($m), USD Actual 2009-2010 131
• Table 78: Microbiology Culture, China, Company share by Revenue ($m), USD Actual 2009-2010 133
• Table 79: Clinical Chemisty Market Pipeline Products 150
• Table 80: Immuno Chemistry Market Pipeline Products 152
• Table 81: Haematology Market Pipeline Products 155
• Table 82: Infectious Immunology Market Pipeline Products 157
• Table 83: Microbiology Culture Market Pipeline Products 161
• Table 84: Histology and Cytology Market Pipeline Products 162
• Table 85: Genetic Testing Market Pipeline Products 163
• Table 86: Mindray Medical International To Acquire Hunan Changsha Tiandiren Biotech 167
• Table 87: Mingyuan Medicare Development To Acquire 70% Stake In Shanghai Yuanqi Bio-Pharmaceutical 168
• Table 88: Mindray Medical To Acquire Controlling Stake In Suzhou Hyssen Electronics 169
• Table 89: BioTime Enters Into Distribution Agreement With USCN Life Science 170
• Table 90: Dolomite Enters Into Co-Development Agreement With Clearbridge BioMedics 171
• Table 91: Institut Pasteur Korea Enters Into Co-Development Agreement With Sanofi-Aventis Korea 172
• Table 92: Rosetta Genomics Enters Into Licensing Agreement With Avatao Biotech 173
• Table 93: Bioo Scientific Enters Into Co-Development Agreement With JungWoo 174
• Table 94: Grifols Enters Into Distribution Agreement With Kainos Laboratories 175
• Table 95: Sigma Aldrich Enters Into Licensing Agreement With HealthLinx 176
• Table 96: Universal Biosensors Enters Into Licensing Agreement With SpeeDx 177
• Table 97: Universal Biosensors Enters Into Co-Development Agreement With Siemens Healthcare Diagnostics 178
• Table 98: Sun Yat-sen University Enters Into Co-Development Agreement With BioDesign Institute 179
• Table 99: Enigma Diagnostics Enters Into Co-Development Agreement With GlaxoSmithKline 180
• Table 100: Eppendorf Enters Into Distribution Agreement With AITBIOTECH 181
• Table 101: Clinical Genomics Extends Its Licensing Agreement With Quest Diagnostics 182
• Table 102: Beijing GP Medical Enters Into Co-Marketing Agreement With Gaoxin Da An 183
• Table 103: National Cancer Center Enters Into Research Agreement With Shimadzu 184
• Table 104: Radient Pharmaceuticals Enters Into Distribution Agreement With Super Religare Laboratories 185
• Table 105: Transasia Enters Into Distribution Agreement With Gen-Probe 186
• Table 106: Transasia Enters Into Distribution Agreement With InTec 187
• Table 107: Akonni Biosystems Enters Into Licensing Agreement With Seegene 188
• Table 108: Royal Philips Electronics Enters Into Co-Development Agreement With NEC 189
• Table 109: Precision System Science Enters Into Co-Development Agreement With Biotrin International 190
• Table 110: Genetic Technologies Enters Into Co-Development Agreement With A Global Pharmaceutical Company 191
• Table 111: Kyowa Medex Enters Into Co-Marketing Agreement With Toyobo 192
• Table 112: Seegene Enters into Co-Development Agreement With Samsung Medical Center 193
• Table 113: IPSOGEN Enters Into Distribution Agreement With Sysmex 194
• Table 114: Transasia Enters Into Distribution Agreement Vircell Microbiologists 195
• Table 115: Vermillion Signs Agreement With Quest Diagnostics 196
• Table 116: IRIS International Enters Into Co-Development Agreement With Fujirebio 197
• Table 117: SuperNova Diagnostics Enters Into An Agreement With Shenzhen Kang Sheng Bao Bio-Technology 198
• Table 118: CJ Pharma Research India Enters Into Development And Licensing Agreement With PeopleBio 199
• Table 119: Pacific Edge Enters Into Licensing Agreement With Healthscope 200
• Table 120: Seegene Enters Into An Agreement With Molzym 201
• Table 121: Ascent Scientific Enters Into Licensing Agreement With Children's Memorial Hospital And The University Of Newcastle 202
• Table 122: Pacgen Biopharmaceuticals Enters Into Agreement With General Biologicals 203
• Table 123: Genomic Expression Enters Into An Agreement With Copenhagen University, Beijing Genome Institute And Bavarian Nordic 204
• Table 124: Innogene Kalbiotech Enters Into Distribution Agreement With Agendia 205
• Table 125: NorDiag Enters Into Agreement With Precision System Science 206
• Table 126: AB Sciex Enters Into Co-Development Agreement With ARUP Laboratories 207
• Table 127: Avacta Group Enters Into Distribution Agreement With Cold Spring Biotech 208
• Table 128: Caliper Life Sciences Enters Into An Agreement With Seegene 209
• Table 129: Trivitron Enters Into Distribution Agreement With Celerus Diagnostics 210
• Table 130: USD to Local Currency, Asia-Pacific, Average Exchange Rate 2003-2010 252

List of Figures

1.2 List of Figures

• Figure 1: In Vitro Diagnostics, Cross Country Comparison, USD Actual, 2003-2017 19
• Figure 2: In Vitro Diagnostics, Asia-Pacific, Overall Revenue ($m), USD Actual, 2003-2017 20
• Figure 3: In Vitro Diagnostics, Asia-Pacific, Cross-Category Analysis, 2003-2017 22
• Figure 4: In Vitro Diagnostics, Asia-Pacific, Overall Revenue ($m), USD Actual, Historic, 2003-2010 24
• Figure 5: In Vitro Diagnostics, Asia-Pacific, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 26
• Figure 6: In Vitro Diagnostics, Asia-Pacific, Company Share (%), 2010 28
• Figure 7: In Vitro Diagnostics, Australia, Overall Revenue ($m), USD Actual, 2003-2017 30
• Figure 8: In Vitro Diagnostics, Australia, Overall Revenue ($m), USD Actual, Historic, 2003-2010 32
• Figure 9: In Vitro Diagnostics, Australia, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 34
• Figure 10: In Vitro Diagnostics, Australia, Company share (%), 2010 40
• Figure 11: Clinical Chemistry, Australia, Company share (%), 2010 42
• Figure 12: Genetic Testing, Australia, Company share (%), 2010 44
• Figure 13: Haematology, Australia, Company share (%), 2010 46
• Figure 14: Histology and Cytology, Australia, Company share (%), 2010 48
• Figure 15: Immuno Chemistry, Australia, Company share (%), 2010 50
• Figure 16: Infectious Immunology, Australia, Company share (%), 2010 52
• Figure 17: Microbiology Culture, Australia, Company share (%), 2010 54
• Figure 18: In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Actual, 2003-2017 56
• Figure 19: In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Actual, Historic, 2003-2010 58
• Figure 20: In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 60
• Figure 21: In Vitro Diagnostics, Japan, Company Share (%), 2010 66
• Figure 22: Clinical Chemistry, Japan, Company Share (%), 2010 68
• Figure 23: Genetic Testing, Japan, Company Share (%), 2010 70
• Figure 24: Haematology, Japan, Company Share (%), 2010 72
• Figure 25: Histology and Cytology, Japan, Company Share (%), 2010 74
• Figure 26: Immuno Chemistry, Japan, Company Share (%), 2010 76
• Figure 27: Infectious Immunology, Japan, Company Share (%), 2010 78
• Figure 28: Microbiology Culture, Japan, Company Share (%), 2010 80
• Figure 29: In Vitro Diagnostics, India, Overall Revenue ($m), USD Actual, 2003-2017 82
• Figure 30: In Vitro Diagnostics, India, Overall Revenue ($m), USD Actual, Historic, 2003-2010 84
• Figure 31: In Vitro Diagnostics, India, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 86
• Figure 32: In Vitro Diagnostics, India, Company Share (%), 2010 92
• Figure 33: Clinical Chemistry, India, Company Share (%), 2010 94
• Figure 34: Genetic Testing, India, Company Share (%), 2010 96
• Figure 35: Haematology, India, Company Share (%), 2010 98
• Figure 36: Histology And Cytology, India, Company Share (%), 2010 100
• Figure 37: Immuno Chemistry, India, Company Share (%), 2010 102
• Figure 38: Infectious Immunology, India, Company Share (%), 2010 104
• Figure 39: Microbiology Culture, India, Company Share (%), 2010 106
• Figure 40: In Vitro Diagnostics, China, Overall Revenue ($m), USD Actual, 2003-2017 108
• Figure 41: In Vitro Diagnostics, China, Overall Revenue ($m), USD Actual, Historic, 2003-2010 110
• Figure 42: In Vitro Diagnostics, China, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 112
• Figure 43: In Vitro Diagnostics, China, Company share (%), 2010 118
• Figure 44: Clinical Chemistry, China, Company share (%), 2010 120
• Figure 45: Genetic Testing, China, Company share (%), 2010 122
• Figure 46: Haematology, China, Company share (%), 2010 124
• Figure 47: Histology And Cytology, China, Company share (%), 2010 126
• Figure 48: Immuno Chemistry, China, Company share (%), 2010 128
• Figure 49: Infectious Immunology, China, Company share (%), 2010 130
• Figure 50: Microbiology Culture, China, Company share (%), 2010 132
• Figure 51: F. Hoffmann-La Roche Ltd., Company Share (%), Asia-Pacific In Vitro Diagnostics Market, 2010 134
• Figure 52: Siemens Healthcare, Company Share (%), Asia-Pacific In Vitro Diagnostics Market, 2010 135
• Figure 53: Abbott Laboratories, Company Share (%), Asia-Pacific In Vitro Diagnostics Market, 2010 136
• Figure 54: Sysmex Corporation, Company Share (%), Asia-Pacific In Vitro Diagnostics Market, 2010 137
• Figure 55: Beckman Coulter, Inc., Company Shar (%), Asia-Pacific In Vitro Diagnostics Market, 2010 138
• Figure 56: Ortho-Clinical Diagnostics Inc., Company Share (%), Asia-Pacific In Vitro Diagnostics Market, 2010 139

相關商品

體外診斷設備相關市場調查報告書

全球切片設備市場:開發平台分析，競爭環境，到2018年為止的市場預測
Biopsy Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
價格 : US $ 3995
出版日期 : 2012年04月

全球分子診斷市場:各國的設施·檢驗數量·銷售額預測
2012 World Molecular Diagnostics Market Overview: Facilities, Test Volumes, and Sales Forecasts by Country
價格 : US $ 1850
出版日期 : 2012年04月

全球微生物測試市場展望：成長機會及業務拓展策略
2012 Microbiology Testing Market Outlook: Growth Opportunities and Strategies
價格 : US $ 28700
出版日期 : 2012年04月

GlobalData發行的醫療設備相關市場調查報告書

全球先進型創傷管理市場:開發平台分析，競爭環境，到2018年為止的市場預測

Advanced Wound Management - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018

價格 : US $ 3995

出版日期 : 2012年04月

臨床化學:全球性開發平台分析，競爭情形，到2018年為止的市場未來預測

Clinical Chemistry - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018

價格 : US $ 3995

出版日期 : 2012年04月

免疫化學分析儀與檢查套件:全球性開發平台分析，競爭情形，到2018年為止的市場未來預測

Immunochemistry Analyzers and Test Kits - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018

價格 : US $ 3995

出版日期 : 2012年04月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!